IPP Bureau
GE HealthCare to acquire Intelerad for $2.3 billion, expanding cloud and AI imaging footprint
By IPP Bureau - November 25, 2025
The deal accelerates GE HealthCare’s digital transformation, expanding its reach into outpatient care and enterprise imaging—a $2 billion-plus growth market
Gilead delivers groundbreaking HIV prevention drug to Eswatini & Zambia
By IPP Bureau - November 25, 2025
The deliveries bring the innovative medicine to communities heavily impacted by HIV just five months after U.S. FDA approval
Zydus receives FDA’s final approval for Verapamil Hydrochloride ER tablets
By IPP Bureau - November 25, 2025
Eris Lifesciences consolidates its stake in Swiss Parenterals
By IPP Bureau - November 25, 2025
The proposed transaction will be effected as a share swap
FDA nod to groundbreaking bladder cancer combo therapy for surgery patients
By IPP Bureau - November 24, 2025
Call it a major milestone in bladder cancer therapy that aims to provide a lifeline for patients who previously had limited options
Marksans Pharma Inc. receives USFDA approval for Loperamide Hydrochloride Tablets
By IPP Bureau - November 24, 2025
Loperamide Hydrochloride is an anti-diarrheal medication used to control symptoms of acute and chronic diarrhoea
Shilpa Medicare receives 8 observations from USFDA for Unit 4 at Jadcherla
By IPP Bureau - November 24, 2025
The Unit is approved by major regulators like EMA, Europe; Health Canada, Anvisa, Brazil and TGA, Australia
Aptus Pharma enters into urology therapy segment
By IPP Bureau - November 24, 2025
The company will soon be launching a new portfolio of products in this segment
Lupin receives 7 observations from USFDA for Goa manufacturing facility
By IPP Bureau - November 24, 2025
Lupin will address the observations and respond to the U.S. FDA within the stipulated timeframe
NATCO Pharma receives 7 observations from USFDA for API unit at Manali
By IPP Bureau - November 24, 2025
Ind-Swift Laboratories receives certifications from Bureau Veritas
By IPP Bureau - November 24, 2025
These certifications reflect the company's continuous commitment to maintaining international standards of environmental sustainability as well as occupational health and safety
FDA slaps gene therapy Elevidys with boxed warning after fatal liver failures
By IPP Bureau - November 24, 2025
Elevidys came under scrutiny in June when the FDA disclosed two fatal cases in non-ambulatory boys who developed dangerously high liver enzyme levels
FDA investigates fatal case linked to rare blood disorder drug Adzynma
By IPP Bureau - November 24, 2025
Adzynma, approved for both adults and children with cTTP, is a recombinant enzyme therapy designed to replace the deficient ADAMTS13 enzyme
Moderna bags $1.5 billion 5-Yr loan to boost financial flexibility
By IPP Bureau - November 24, 2025
The non-dilutive financing includes three tranches
Bayer’s experimental stroke drug could reshape secondary stroke prevention
By IPP Bureau - November 24, 2025
Millions of stroke survivors across the world may soon have a new defense
